Dayvigo vs Trazodone: What To Do When One Fails

How Dayvigo and Trazodone Work Differently

Dayvigo (lemborexant) blocks orexin-1 and orexin-2 receptors, turning off the brain's wakefulness signaling rather than sedating through broad CNS depression. Trazodone inhibits serotonin reuptake and blocks histamine H1 and alpha-1 adrenergic receptors at the lower doses used for sleep, producing sedation through a different route entirely. Understanding this mechanistic separation is the foundation for any rational switching decision.

The Orexin System vs. Histaminergic Sedation

The orexin system promotes wakefulness. Blocking it with lemborexant at 5 mg or 10 mg allows natural sleep pressure to win without artificially deepening sedation. SUNRISE-1 (N=1,006, JAMA Netw Open 2019) demonstrated that lemborexant 10 mg reduced subjective sleep onset latency (sSOL) by 28.4 minutes from baseline versus a reduction of 11.1 minutes with placebo at month 6. [1] That trial also showed improvement in subjective wake after sleep onset (sWASO) by 40.4 minutes for the 10 mg dose. [1]

Trazodone's sleep effect at 50-150 mg is driven predominantly by histamine H1 blockade and alpha-1 antagonism. Mendelson (J Clin Psychiatry 2005) showed that trazodone 50-100 mg produced statistically significant improvements in polysomnographic total sleep time, sleep efficiency, and wake after sleep onset in patients with primary insomnia over two weeks. [2] Because the serotonin reuptake inhibition becomes more prominent at higher doses, trazodone used for sleep typically stays at 50-100 mg to minimize next-day serotonergic side effects.

Why the Mechanism Gap Matters for Switching

A patient failing lemborexant may have hypersensitivity to residual orexin activity (i.e., the drug is simply not suppressing wakefulness drive enough at 10 mg). Switching to trazodone adds a sedating histaminergic effect that operates on a completely separate pathway. The American Academy of Sleep Medicine (AASM) Clinical Practice Guidelines note that different pharmacological classes may be tried sequentially when the first agent is ineffective or not tolerated. [3] Conversely, a patient failing trazodone due to morning grogginess or orthostatic hypotension may benefit from the more targeted, receptor-specific profile of lemborexant.

Common Reasons Dayvigo (Lemborexant) Fails

Lemborexant fails for several distinct reasons. Identifying the specific failure mode determines whether a switch is necessary or whether a dose adjustment within the DORA class is more appropriate.

Inadequate Sleep Maintenance Despite 10 mg

Lemborexant's maximum approved dose is 10 mg. If a patient has tried 5 mg for at least two weeks and then escalated to 10 mg for another two weeks with no improvement in sWASO, the orexin-blockade ceiling has effectively been reached. The FDA prescribing information for lemborexant lists 10 mg as the maximum recommended dose, and doses above this have not been evaluated for safety or efficacy. [4]

Next-Day Impairment and Driving Risk

SUNRISE-1 found that 10.7% of lemborexant 10 mg users reported somnolence as an adverse event versus 2.8% placebo. [1] Next-morning driving simulation studies showed impairment at the 10 mg dose, particularly in women and older adults, which led the FDA to recommend that women start at 5 mg. [4] A patient who cannot tolerate residual sedation even at 5 mg is a clear candidate for a mechanistically different option.

Cost and Insurance Coverage

Lemborexant carries a brand-only price of roughly $400-500 per month without insurance. Trazodone, available generically, costs under $15 per month at most pharmacies. The GoodRx database reflects a median cash price of approximately $10-12 for 30 tablets of trazodone 100 mg. When cost is the primary failure reason, switching to trazodone is appropriate provided the patient's insomnia profile fits the sedating-antidepressant mechanism.

Common Reasons Trazodone Fails

Trazodone is prescribed off-label for insomnia more than any other antidepressant in the United States, yet its evidence base for chronic primary insomnia is comparatively thin. A 2018 Cochrane-adjacent systematic review of pharmacological treatments for insomnia found that trazodone had fewer high-quality randomized controlled trials than benzodiazepine receptor agonists or DORAs, and effect sizes were more variable. [5]

Orthostatic Hypotension and Falls Risk

Alpha-1 adrenergic blockade causes vasodilation and orthostatic hypotension. The FDA-approved labeling for trazodone includes a warning about hypotension, syncope, and falls, especially in elderly patients. [6] For a 70-year-old patient already on an antihypertensive, a single trazodone 50 mg dose could drop standing blood pressure by 10-20 mmHg. Switching to lemborexant eliminates this risk pathway entirely, since DORAs have no significant adrenergic activity.

Priapism and Male Patients

Trazodone carries a black-box warning for priapism, a rare but serious urological emergency requiring immediate intervention if erection persists beyond four hours. [6] Male patients who report prolonged or painful erections on trazodone must discontinue the drug immediately, and lemborexant becomes an appropriate alternative given its absence of adrenergic or serotonergic effects at the receptor level.

Tachyphylaxis After Weeks to Months

Some patients report that trazodone works well for the first four to eight weeks then loses effect as tolerance to the histamine-blocking and adrenergic-blocking components develops. A controlled study of trazodone in primary insomnia by Roth et al. (Sleep Med 2011) found that polysomnographic benefits at week 2 were partially attenuated by week 4 in some subjects. [7] Lemborexant, with its mechanistically distinct orexin-targeted approach, does not show the same pattern of rapid tachyphylaxis in short-term trial data.

How To Switch From Dayvigo to Trazodone

Switching from lemborexant to trazodone is a straightforward process given the short half-lives involved. Lemborexant's half-life is 17-19 hours, meaning near-complete elimination within 4-5 days at most. Trazodone's half-life is approximately 5-9 hours for the parent compound.

Step 1: Stop Lemborexant the Night Before Starting Trazodone

No formal taper is needed for lemborexant. The FDA prescribing information does not list a discontinuation syndrome for DORAs, and SUNRISE-1 extension data showed no rebound insomnia signal above baseline after stopping lemborexant 10 mg at 12 months. [1] Stop the drug on night N and start trazodone at 50 mg on night N+1.

Step 2: Start Trazodone at 50 mg and Titrate Slowly

The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommend starting trazodone at the lowest effective dose and titrating based on response and tolerability. [3] Begin at 50 mg taken 30 minutes before bedtime. If sleep is inadequate after one to two weeks and morning sedation is acceptable, increase to 75 mg or 100 mg. Most sleep-focused dosing stays below 150 mg to minimize daytime serotonergic burden.

Step 3: Monitor for Orthostatic Hypotension in the First Week

Check standing blood pressure in the morning on days 3 and 7 after starting trazodone, particularly in patients over 60 or those on antihypertensives, diuretics, or alpha-blockers. A drop of more than 20 mmHg systolic or 10 mmHg diastolic on standing qualifies as clinically significant orthostasis. [8]

How To Switch From Trazodone to Dayvigo

Patients switching from trazodone to lemborexant are typically doing so because of tolerability concerns (sedation, falls risk, or priapism warning), or because trazodone has lost effect. The FDA prescribing information for lemborexant does not require any specific washout from trazodone before initiation. [4]

Taper Trazodone Before Starting Lemborexant

Unlike lemborexant, trazodone does have a discontinuation syndrome at higher doses and in long-term users. The FDA labeling for trazodone recommends gradual dose reduction rather than abrupt discontinuation whenever possible. [6] For a patient on trazodone 100 mg, reduce to 50 mg for five to seven days, then stop. Start lemborexant at 5 mg the night after the final trazodone dose.

Titrate Lemborexant Based on Sex and Age

Women metabolize lemborexant more slowly than men. SUNRISE-1 pharmacokinetic data showed that maximum plasma concentration (Cmax) was approximately 30-40% higher in women than men at the same dose. [1] Women should begin at 5 mg and remain at that dose for at least four weeks before any discussion of escalation to 10 mg. Men over 65 should also start at 5 mg given age-related CYP3A4 activity reduction. [4]

Expect a Two-Week Adjustment Period

Some patients report a brief period of lighter sleep during the first one to two weeks after switching from a sedating agent like trazodone to a DORA. The brain has been accustomed to histaminergic suppression; removing it while the orexin system re-calibrates may temporarily shorten total sleep time. Set realistic expectations with the patient before the switch.

Comparing Efficacy Head-to-Head

No published randomized controlled trial has directly compared lemborexant against trazodone for insomnia in the same patient population. This is a gap in the literature worth acknowledging explicitly.

What SUNRISE-1 Shows for Lemborexant

SUNRISE-1 (N=1,006) randomized adults with insomnia disorder to lemborexant 5 mg, lemborexant 10 mg, or placebo for six months. [1] At month 1, lemborexant 10 mg reduced sSOL by a mean of 30.6 minutes from baseline versus 12.7 minutes for placebo (P<0.001). By month 6, sWASO was reduced by 40.4 minutes for 10 mg versus 19.8 minutes for placebo. Subjective sleep quality scores on the PSQI improved by 4.4 points for 10 mg versus 2.3 points for placebo (P<0.001). [1]

What Mendelson 2005 Shows for Trazodone

Mendelson (J Clin Psychiatry 2005, N=35) conducted a two-week randomized crossover study comparing trazodone 50 mg to zolpidem 10 mg and placebo in patients with primary insomnia. [2] Trazodone significantly improved polysomnographic sleep efficiency (SE) and total sleep time (TST) versus placebo, but was numerically inferior to zolpidem on objective sleep onset latency. The authors concluded that trazodone "represents a reasonable treatment option for patients with primary insomnia, particularly those unable to use controlled substances." [2]

Indirect Comparison: Lemborexant Appears More Strong on Sleep Maintenance

Across separate trial populations, lemborexant 10 mg produced larger reductions in sWASO (40.4 minutes at 6 months) than the reductions seen in the trazodone literature (approximately 15-25 minutes in Mendelson 2005 and similar short trials). [1][2] This indirect comparison is hypothesis-generating only. Patient populations, outcome measures, and trial durations differ substantially. A direct RCT is needed.

Special Populations: Who Should Get Which Drug First

Patient characteristics should guide the initial choice and the switch decision more than trial data alone.

Older Adults (Age 65 and Over)

Both drugs carry specific cautions in older patients. The American Geriatrics Society Beers Criteria 2023 lists trazodone as a potentially inappropriate medication in older adults due to orthostatic hypotension and falls risk. [9] Lemborexant is not included on the 2023 Beers list, though the FDA label recommends starting at 5 mg in this group. For older adults failing trazodone due to falls or hypotension, lemborexant 5 mg is a well-supported alternative.

Patients With Comorbid Depression

Trazodone is FDA-approved for major depressive disorder and may provide dual benefit in patients with insomnia plus mild-to-moderate depression. The 2023 APA Practice Guidelines for Major Depressive Disorder do not position trazodone as a first-line antidepressant, but it retains a role as an augmentation agent for sleep in patients already on an SSRI or SNRI. [10] Lemborexant has no antidepressant activity, so patients with significant depressive symptoms should not switch away from trazodone without addressing the mood component separately.

Patients on Opioids or CNS Depressants

The FDA prescribing information for lemborexant warns of additive CNS depression with opioids, alcohol, and other sedative-hypnotics, and recommends avoiding the 10 mg dose in these patients. [4] Trazodone carries a similar warning. Neither drug has a safety advantage over the other in this population. CBT-I (Cognitive Behavioral Therapy for Insomnia) should be prioritized as the primary intervention, per the AASM 2021 position statement on CBT-I. [11]

When Neither Drug Works: The Next Steps

If a patient has failed both lemborexant at 10 mg for six weeks and trazodone at 100 mg for six weeks, the clinical approach should shift before adding a third agent.

Rule Out Sleep Apnea and Restless Legs Syndrome

Undiagnosed obstructive sleep apnea (OSA) accounts for a significant proportion of apparent insomnia treatment failures. The AASM estimates that up to 30% of adults with insomnia have co-occurring OSA. [12] A home sleep apnea test or in-lab polysomnography should precede any third pharmacological trial. Restless legs syndrome (RLS) also disrupts sleep initiation and maintenance in a way that neither lemborexant nor trazodone specifically addresses.

Prioritize CBT-I Before a Third Drug

The AASM Clinical Practice Guideline (2021) gives CBT-I a strong recommendation as first-line treatment for chronic insomnia disorder in adults, ahead of any pharmacotherapy. [11] Six to eight weekly sessions of CBT-I produce response rates of 70-80% in randomized trials. A 2015 meta-analysis by Van Straten et al. (Sleep Medicine Reviews) covering 14 RCTs (N=1,162) found that CBT-I improved sleep efficiency by a standardized mean difference of 1.09 versus control. [13] If CBT-I has not been tried, a prescription for a third sleep drug without offering it represents a missed opportunity.

Consider Low-Dose Doxepin or Suvorexant

If a third pharmacological agent is clinically appropriate after OSA exclusion and CBT-I completion, low-dose doxepin (3 mg or 6 mg) and suvorexant (another DORA, 10-20 mg) have FDA approval for insomnia. The FDA prescribing information for low-dose doxepin shows significant improvement in sleep maintenance in elderly patients at 3 mg. [14] Suvorexant's trial program (TRIAL 1 and TRIAL 2, N=1,021 combined) demonstrated a significant reduction in total wake time versus placebo at doses of 15-20 mg. [15]

Practical Prescribing Summary

The table below summarizes the key decision points for switching between lemborexant and trazodone.

| Decision Point | Dayvigo (Lemborexant) | Trazodone | |---|---|---| | Starting dose for insomnia | 5 mg (women and elderly: mandatory start) | 50 mg | | Maximum insomnia dose | 10 mg | 150 mg (sleep-focused) | | Half-life | 17-19 hours | 5-9 hours | | DEA Schedule | Schedule IV | None | | Discontinuation taper needed | No | Yes (at higher doses or long duration) | | Primary failure reasons | Cost, residual sedation at 10 mg | Orthostasis, priapism risk, tachyphylaxis | | Best next agent when failing | Trazodone 50 mg (cost), CBT-I | Lemborexant 5 mg (tolerability), CBT-I |